New hope for leukemia: immunotherapy combo aims to beat relapse

NCT ID NCT06860269

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Feb 16, 2026 · Last updated Apr 28, 2026 · Updated 8 times

Summary

This study is for adults aged 18–65 newly diagnosed with acute lymphoblastic leukemia (ALL). It tests whether adding newer immunotherapy drugs (blinatumomab for B-cell ALL, isatuximab for T-cell ALL) to standard treatment can improve survival and reduce the need for a stem cell transplant. About 1,200 participants will be randomly assigned to receive these new drugs or standard care. The goal is to see if these combinations lead to better long-term outcomes with manageable side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hôpital Saint Louis
RECRUITING

Paris, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE LYMPHOBLASTIC LEUKEMIA